Kwality [KPL] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Kwality
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Kwality wins in 12 metrics, Aarti Drugs wins in 7 metrics, with 0 ties. Kwality appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Kwality | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 25.44 | 22.81 | Aarti Drugs |
| Price-to-Book Ratio | 4.18 | 3.14 | Aarti Drugs |
| Debt-to-Equity Ratio | 42.85 | 44.92 | Kwality |
| PEG Ratio | 0.59 | 0.36 | Aarti Drugs |
| EV/EBITDA | 13.61 | 16.76 | Kwality |
| Profit Margin (TTM) | 10.81% | 7.80% | Kwality |
| Operating Margin (TTM) | 17.75% | 10.11% | Kwality |
| EBITDA Margin (TTM) | 17.75% | 10.11% | Kwality |
| Return on Equity | 15.19% | 12.28% | Kwality |
| Return on Assets (TTM) | 8.91% | 6.53% | Kwality |
| Free Cash Flow (TTM) | $277.15M | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | 40.60% | -14.34% | Kwality |
| Price-to-Sales Ratio (TTM) | 2.75 | 1.77 | Aarti Drugs |
| Enterprise Value | $12.00B | $49.56B | Aarti Drugs |
| EV/Revenue Ratio | 2.99 | 2.05 | Aarti Drugs |
| Gross Profit Margin (TTM) | 47.94% | 36.77% | Kwality |
| Revenue per Share (TTM) | $387 | $265 | Kwality |
| Earnings per Share (Diluted) | $41.80 | $20.65 | Kwality |
| Beta (Stock Volatility) | -0.18 | 0.21 | Kwality |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Kwality vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Kwality | -2.05% | 1.27% | -11.51% | 6.54% | 45.37% | 16.77% |
| Aarti Drugs | 2.56% | -4.13% | -10.00% | 1.76% | 27.10% | 6.05% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Kwality | 40.60% | 248.32% | 2,317.06% | 4,401.11% | 4,401.11% | 4,401.11% |
| Aarti Drugs | -14.34% | 10.27% | -34.08% | 237.25% | 2,680.94% | 2,426.41% |
Performance & Financial Health Analysis: Kwality vs Aarti Drugs
| Metric | KPL | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹11.03B | ₹42.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 26,054 | 149,023 |
| 90 Day Avg. Volume | 23,175 | 593,839 |
| Last Close | ₹1,012.75 | ₹483.05 |
| 52 Week Range | ₹596.05 - ₹1,235.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -18.00% | -23.93% |
| All-Time High | ₹1,235.00 (Jul 07, 2025) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -18.00% | -52.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.39% | 0.06% |
| Quarterly Earnings Growth | 0.43% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.08% |
| Operating Margin (TTM) | 0.18% | 0.10% |
| Return on Equity (TTM) | 0.15% | 0.12% |
| Debt to Equity (MRQ) | 42.85 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹254.23 | ₹149.84 |
| Cash per Share (MRQ) | ₹14.22 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹392.43M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹398.45M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | ₹0.00 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Kwality vs Aarti Drugs
| Metric | KPL | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 25.44 | 22.81 |
| Forward P/E | N/A | 14.86 |
| PEG Ratio | 0.59 | 0.36 |
| Price to Sales (TTM) | 2.75 | 1.77 |
| Price to Book (MRQ) | 4.18 | 3.14 |
| Market Capitalization | ||
| Market Capitalization | ₹11.03B | ₹42.99B |
| Enterprise Value | ₹12.00B | ₹49.56B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.99 | 2.05 |
| Enterprise to EBITDA | 13.61 | 16.76 |
| Risk & Other Metrics | ||
| Beta | -0.18 | 0.21 |
| Book Value per Share (MRQ) | ₹254.23 | ₹149.84 |
Financial Statements Comparison: Kwality vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | KPL | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹1.11B | ₹6.77B |
| Cost of Goods Sold | ₹580.34M | ₹4.37B |
| Gross Profit | ₹534.45M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹194.12M | ₹784.50M |
| EBITDA | ₹245.52M | ₹951.90M |
| Pre-Tax Income | ₹170.28M | ₹711.50M |
| Income Tax | ₹51.08M | ₹83.80M |
| Net Income (Profit) | ₹119.20M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | KPL | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹120.20M | ₹45.80M |
| Total Current Assets | ₹2.84B | ₹13.38B |
| Total Current Liabilities | ₹1.70B | ₹8.37B |
| Long-Term Debt | ₹151.19M | ₹2.86B |
| Total Shareholders Equity | ₹2.62B | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹1.44B | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | KPL | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | ₹-36.22M | N/A |
| Capital Expenditures | ₹-13.09M | N/A |
| Free Cash Flow | ₹-14.05M | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | KPL | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 26,054 | 149,023 |
| Average Daily Volume (90 Day) | 23,175 | 593,839 |
| Shares Outstanding | 10.38M | 91.27M |
| Float Shares | 2.30M | 35.46M |
| % Held by Insiders | 0.77% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Kwality vs Aarti Drugs
| Metric | KPL | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | ₹0.00 | ₹3.00 |
| Ex-Dividend Date | N/A | Feb 04, 2025 |